Graduating in Biology from the Universidad de Granada (Spain), Amancio Carnero began his scientific career in the Genetics Department at the same University where he spent two years as an undergraduate student. He then moved to the Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC, Madrid and carried out his PhD studies at the Department of Molecular Biology at the Universidad Autónoma de Madrid. Amancio Carnero worked on the signal transduction mechanisms induced by Ras oncogenes. He found that Ras activates a Phopholipase D and that the results of such activation have a role in mitogenesis. Upon completing his PhD in 1994 he was an Associate Professor at the Department of Biochemistry, the Universidad Autónoma de Madrid, from where he moved in January 1996 to the Cold Spring Harbor Laboratory, New York, USA, as a Postdoc in the laboratory of D. H. Beach. When D. Beach’s lab moved to London, Amancio returned to Europe as a Senior Research Fellow at the Institute of Child Health and Great Ormond Street Hospital, University College London (UCL), UK where he worked to improve methods for identifying new molecular targets based on functional screenings (either by gain or loss-of-function). His research interests focused on the cell cycle, cellular senescense and cellular immortalisation. He then spent another two years in London at the Wolfson Institute for Biomedical Research (UCL) as a Senior Lecturer before returning to Spain in 2001 to assume his current position as Head of the CNIO’s Assay Development Section in the Experimental Therapeutics Programme. During 9 years He worked at the CNIO developing the preclinical platform to identify new antitumor therapies. At the end of 2009, Amancio move to the Institut of biomedicine of Seville were He followed his work in The identification and characterization of genes with therapeutic relevance in cancer, Establishing the causality during tumor initiation and progression, Validation of new therapeutic targets.

The research lines in this laboratory are: • Identification and characterization of genes with therapeutic relevance in cancer. • Establishing causality in the initiation and progression of the tumoral process. • Validation of new therapeutic targets that could form the basis for the identification of new anti-tumor compounds.